United Therapeutics's earnings per share without non-recurring items for the
three
months ended in Mar. 2026 was $5.82.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $27.46.
During the past 12 months, United Therapeutics's average earnings per share (NRI) Growth Rate was 4.70% per year.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 23.40% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was 16.00% per year.
During the past 10 years, the average earnings per share (NRI) Growth Rate was 6.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for United Therapeutics's EPS without NRI or its related term are showing as below:
UTHR'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -39.4 Med: 15.45 Max: 155.3
Current: 23.4
During the past 13 years, United Therapeutics's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 155.30% per year. The lowest was -39.40% per year. And the median was 15.45% per year.
UTHR's 3-Year EPS without NRI Growth Rate is ranked better than 70.01% of 787
companies
in the Drug Manufacturers industry
Industry Median: 9.7
vs UTHR: 23.40
United Therapeutics's EPS (Basic) for the
three
months ended in Mar. 2026 was $6.32.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $29.32.
United Therapeutics (NAS:UTHR) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
United Therapeutics EPS without NRI Related Terms
United Therapeutics EPS without NRI Historical Data
* Premium members only.
The historical data trend for United Therapeutics's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UTHR vs VTRS, NBIX, ZTS: EPS without NRI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, United Therapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Therapeutics PE Ratio without NRI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, United Therapeutics's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where United Therapeutics's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $27.46
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Therapeutics (UTHR) has a EPS without NRI of $27.46 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on United Therapeutics and its competitors. According to the industry distribution chart, United Therapeutics ranks #236 out of 787 companies in the Drug Manufacturers industry, placing it in the top 30%.
Is United Therapeutics' EPS without NRI too high?
United Therapeutics' current EPS without NRI is $27.46. The Drug Manufacturers industry median EPS without NRI is 9.70. United Therapeutics' value of $27.46 is 183.1% above this industry median. Based on the distribution chart, United Therapeutics ranks #236 out of 787 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, United Therapeutics has a GF Score™ of 88/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' EPS without NRI compare to VTRS and NBIX?
According to the Drug Manufacturers industry distribution chart, United Therapeutics ranks #236 out of 787 companies for EPS without NRI. This puts United Therapeutics in the upper half of its industry. The industry median EPS without NRI is 9.70. United Therapeutics' value of $27.46 is 183.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.70, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. United Therapeutics's current EPS without NRI of $27.46 is 183.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on United Therapeutics and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. United Therapeutics's current EPS without NRI is $27.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (UTHR) is currently considered Significantly Overvalued. The stock's GF Value™ is $386.63, compared to a current price of $556.11 — trading 43.8% above its estimated fair value. The current EPS without NRI is $27.46 and 183.1% above the Drug Manufacturers industry median of 9.70. United Therapeutics' overall GF Score™ is 88/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For United Therapeutics (UTHR), the current EPS without NRI is $27.46 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is United Therapeutics (UTHR) Overvalued in 2026?
Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued.
The current stock price of $556.11 is trading 43.8% above its estimated GF Value™ of $386.63.
GuruFocus considers United Therapeutics to be Significantly Overvalued.
Key valuation signals for UTHR:
EPS without NRI: $27.46
GF Value™: $386.63 vs. price of $556.11 (43.8% above fair value)
Industry Position: 183.1% above the Drug Manufacturers median (#236 of 787)
No single metric tells the full story. See the UTHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
88GF Score
Get the complete analysis for UTHR
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UTHR has been successfully added to your 
